Related Experiment Video
Updated: Mar 25, 2026
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
673
Controlling levonorgestrel binding and release in a multi-purpose prevention technology vaginal ring device.
Diarmaid J Murphy1, Peter Boyd1, Clare F McCoy1
1School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, United Kingdom.
Summary
This study investigated levonorgestrel binding in silicone elastomers, crucial for drug delivery. Key factors like cure conditions and drug loading influence binding, impacting product development for HIV prevention and contraception.
Area of Science:
- Biomaterials Science
- Polymer Chemistry
- Pharmaceutical Sciences
Background:
- Silicone elastomers are widely used for drug delivery, but irreversible drug binding is poorly understood.
- Levonorgestrel, a contraceptive progestin, is incorporated into these systems for sustained release.
Purpose of the Study:
- To investigate the chemical binding of levonorgestrel with hydrosilane groups in addition-cure silicone elastomers.
- To identify key parameters affecting levonorgestrel binding and its impact on drug delivery.
Main Methods:
- Investigated the chemical interaction between levonorgestrel and silicone elastomer hydrosilane groups.
- Analyzed the influence of cure time, cure temperature, drug particle size, drug loading, and elastomer type on binding.
Main Results:
- Levonorgestrel binding is significantly influenced by cure time, cure temperature, levonorgestrel particle size, initial loading, and silicone elastomer type.
- These parameters affect the solubility of levonorgestrel within the silicone matrix, thereby modulating binding.
Conclusions:
- Understanding and mitigating levonorgestrel binding is essential for developing effective drug delivery systems.
- This research is critical for advancing multi-purpose vaginal ring technology for combined HIV prevention and contraception.
Related Concept Videos
01:21Intrauterine Drug Delivery Systems
126
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
126
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
169
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
169
01:22Birth Control Methods
7.2K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
7.2K
01:26Oral Drug Delivery Systems: Continuous-Release Systems
203
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
203
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
77
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
77